DK2981624T3 - Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling - Google Patents
Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling Download PDFInfo
- Publication number
- DK2981624T3 DK2981624T3 DK14779403.6T DK14779403T DK2981624T3 DK 2981624 T3 DK2981624 T3 DK 2981624T3 DK 14779403 T DK14779403 T DK 14779403T DK 2981624 T3 DK2981624 T3 DK 2981624T3
- Authority
- DK
- Denmark
- Prior art keywords
- assessment
- prediction
- response
- methods
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000007812 deficiency Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000005215 recombination Methods 0.000 title 1
- 230000006798 recombination Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809105P | 2013-04-05 | 2013-04-05 | |
| US201361913762P | 2013-12-09 | 2013-12-09 | |
| PCT/US2014/033014 WO2014165785A2 (en) | 2013-04-05 | 2014-04-04 | Methods and materials for assessing homologous recombination deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2981624T3 true DK2981624T3 (da) | 2020-03-02 |
Family
ID=51659359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14779403.6T DK2981624T3 (da) | 2013-04-05 | 2014-04-04 | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20140363521A1 (enExample) |
| EP (2) | EP2981624B1 (enExample) |
| JP (5) | JP6625045B2 (enExample) |
| AU (3) | AU2014248007B2 (enExample) |
| CA (1) | CA2908745C (enExample) |
| DK (1) | DK2981624T3 (enExample) |
| ES (1) | ES2777228T3 (enExample) |
| PT (1) | PT2981624T (enExample) |
| WO (1) | WO2014165785A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| KR20190002733A (ko) | 2010-12-30 | 2019-01-08 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| CA2839210A1 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| EP3660161B1 (en) | 2011-12-21 | 2024-07-31 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| EP3415915B1 (en) | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| AU2014248007B2 (en) * | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| EP4023765A1 (en) | 2013-12-09 | 2022-07-06 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP3108246B1 (en) | 2014-02-21 | 2019-10-09 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| ES2800673T3 (es) | 2014-08-15 | 2021-01-04 | Myriad Genetics Inc | Métodos y materiales para evaluar una deficiencia de recombinación homóloga |
| ES2989276T3 (es) * | 2014-12-05 | 2024-11-25 | Found Medicine Inc | Análisis multigénico de muestras tumorales |
| US20160160294A1 (en) * | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| US20180148792A1 (en) | 2015-05-19 | 2018-05-31 | T.S. Sridhar | Method for Identification of a Deficient BRCA1 Function |
| AU2016348401A1 (en) * | 2015-11-03 | 2018-05-24 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (CTCs) in metastatic disease to characterize disease heterogeneity |
| WO2017106365A1 (en) * | 2015-12-14 | 2017-06-22 | Myriad Genetics, Inc. | Methods for measuring mutation load |
| WO2017191074A1 (en) * | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| EP3400311A4 (en) * | 2016-01-06 | 2019-07-03 | Epic Sciences, Inc. | GENOMIC INDIVIDUAL CELL PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN METASTASIC DISEASE TO CHARACTERIZE THE DISEASE HETEROGENICITY |
| WO2017165270A1 (en) * | 2016-03-21 | 2017-09-28 | Myriad Genetics, Inc. | Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer |
| WO2017178509A1 (en) | 2016-04-12 | 2017-10-19 | Xentech | Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| WO2017191076A1 (en) | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| EP3478286B1 (en) * | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| EP3802923A4 (en) | 2018-06-11 | 2022-03-16 | Foundation Medicine, Inc. | COMPOSITIONS AND METHODS FOR ASSESSING GENOMIC ALTERATIONS |
| WO2020137076A1 (ja) * | 2018-12-28 | 2020-07-02 | 国立大学法人 東京大学 | Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法 |
| JP7368483B2 (ja) | 2019-02-12 | 2023-10-24 | テンパス ラブズ，インコーポレイテッド | 相同組換え欠損を推定するための統合された機械学習フレームワーク |
| ES2989374T3 (es) | 2019-12-10 | 2024-11-26 | Tempus Ai Inc | Sistemas y procedimientos para predecir el estado de deficiencia de recombinación homóloga de una muestra |
| JP2023506084A (ja) * | 2019-12-16 | 2023-02-14 | アジレント・テクノロジーズ・インク | ゲノム瘢痕アッセイ及び関連する方法 |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN111883211B (zh) * | 2020-08-07 | 2021-04-23 | 张哲� | 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法 |
| US11718869B2 (en) * | 2020-08-12 | 2023-08-08 | Zhenyue Biotechnology Jiangsu Co., Ltd. | Method and kit for determining genome instability based on next generation sequencing (NGS) |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| EP4274908A1 (en) * | 2021-01-10 | 2023-11-15 | Act Genomics (IP) Limited | Homologous recombination deficiency determining method and kit thereof |
| BE1029144B1 (fr) | 2021-02-25 | 2022-09-20 | Oncodna | Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé |
| CN112820351A (zh) * | 2021-03-01 | 2021-05-18 | 江苏医联生物科技有限公司 | 检测肿瘤患者的突变和hrd评分指导用药的方法 |
| WO2022272310A1 (en) * | 2021-06-25 | 2022-12-29 | Foundation Medicine, Inc. | System and method of classifying homologous repair deficiency |
| EP4444914A1 (en) * | 2021-12-08 | 2024-10-16 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency in breast cancer subtypes |
| KR102523938B1 (ko) * | 2022-02-04 | 2023-04-19 | 가톨릭대학교 산학협력단 | 상동 재조합 결핍증 예측 모델의 모델링 방법 |
| EP4605937A1 (en) | 2022-10-19 | 2025-08-27 | Vib Vzw | Method of determining loss of heterozygosity status of a tumor |
| WO2025078387A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| WO2025078404A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| MX9206577A (es) | 1991-11-15 | 1993-05-01 | Smithkline Beecham Corp | COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| ATE478664T1 (de) | 2000-12-01 | 2010-09-15 | Eisai Inc | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| US7754684B2 (en) | 2003-06-11 | 2010-07-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| DE04777189T1 (de) | 2003-07-02 | 2011-04-07 | Solux Corporation, San Diego | Thermisch stabiles kristallines epirubicin-hydrochlorid und herstellungsverfahren dafür |
| ATE454893T1 (de) | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
| DE602004015811D1 (de) | 2003-08-13 | 2008-09-25 | Univ South Florida | Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden |
| MX2007015852A (es) | 2005-06-30 | 2008-02-22 | Bionumerik Pharmaceuticals Inc | Analogos de platino con ligandos de monoazol. |
| KR100925337B1 (ko) * | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| WO2011160063A2 (en) | 2010-06-18 | 2011-12-22 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| EP3415915B1 (en) * | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| AU2014248007B2 (en) * | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
-
2014
- 2014-04-04 AU AU2014248007A patent/AU2014248007B2/en active Active
- 2014-04-04 EP EP14779403.6A patent/EP2981624B1/en active Active
- 2014-04-04 US US14/245,576 patent/US20140363521A1/en not_active Abandoned
- 2014-04-04 ES ES14779403T patent/ES2777228T3/es active Active
- 2014-04-04 DK DK14779403.6T patent/DK2981624T3/da active
- 2014-04-04 JP JP2016506657A patent/JP6625045B2/ja active Active
- 2014-04-04 CA CA2908745A patent/CA2908745C/en active Active
- 2014-04-04 PT PT147794036T patent/PT2981624T/pt unknown
- 2014-04-04 EP EP19216740.1A patent/EP3693475A1/en active Pending
- 2014-04-04 WO PCT/US2014/033014 patent/WO2014165785A2/en not_active Ceased
-
2017
- 2017-07-17 US US15/651,652 patent/US20180030544A1/en not_active Abandoned
-
2019
- 2019-04-26 JP JP2019085187A patent/JP7522539B2/ja active Active
-
2020
- 2020-06-17 AU AU2020204028A patent/AU2020204028B2/en active Active
- 2020-11-25 JP JP2020194936A patent/JP7522643B2/ja active Active
-
2021
- 2021-06-21 US US17/353,279 patent/US20210310079A1/en active Pending
-
2022
- 2022-08-04 AU AU2022211880A patent/AU2022211880B2/en active Active
- 2022-10-21 JP JP2022169085A patent/JP7641938B2/ja active Active
-
2025
- 2025-02-25 JP JP2025027653A patent/JP2025090619A/ja active Pending
- 2025-03-24 US US19/088,496 patent/US20250223655A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2981624A4 (en) | 2016-11-30 |
| JP2016523511A (ja) | 2016-08-12 |
| EP3693475A1 (en) | 2020-08-12 |
| NZ712663A (en) | 2021-07-30 |
| US20180030544A1 (en) | 2018-02-01 |
| AU2014248007A1 (en) | 2015-10-15 |
| EP2981624A2 (en) | 2016-02-10 |
| CA2908745A1 (en) | 2014-10-09 |
| US20250223655A1 (en) | 2025-07-10 |
| EP2981624B1 (en) | 2019-12-18 |
| JP7641938B2 (ja) | 2025-03-07 |
| ES2777228T3 (es) | 2020-08-04 |
| WO2014165785A2 (en) | 2014-10-09 |
| JP6625045B2 (ja) | 2019-12-25 |
| JP2019165731A (ja) | 2019-10-03 |
| US20210310079A1 (en) | 2021-10-07 |
| AU2020204028A1 (en) | 2020-07-09 |
| AU2014248007B2 (en) | 2020-03-26 |
| JP2025090619A (ja) | 2025-06-17 |
| JP7522643B2 (ja) | 2024-07-25 |
| PT2981624T (pt) | 2020-03-23 |
| CA2908745C (en) | 2023-03-14 |
| JP2021036903A (ja) | 2021-03-11 |
| AU2020204028B2 (en) | 2022-08-18 |
| JP7522539B2 (ja) | 2024-07-25 |
| AU2022211880B2 (en) | 2025-05-29 |
| US20140363521A1 (en) | 2014-12-11 |
| AU2022211880A1 (en) | 2022-09-01 |
| JP2023012488A (ja) | 2023-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2981624T3 (da) | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling | |
| IL295860B1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| IL283586A (en) | Methods and processes for non-invasive assessment of genetic variations | |
| DK3074534T3 (da) | Fremgangsmåder til polynukleotidsekventering | |
| DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
| DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
| CL2016001212A1 (es) | Moduladores de aplnr y usos de estos | |
| DK2840593T3 (da) | Forbedret afbryderindretning og fremgangsmåde til fremstilling dertil | |
| IL240388A0 (en) | Methods of treating melanoma | |
| DK3087095T3 (da) | FcRn-antagonist og fremgangsmåder til anvendelse | |
| DK3009021T3 (da) | Handske og fremgangsmåde til fremstilling deraf | |
| HUE055465T2 (hu) | PD-L1 ellenes humán antitestek | |
| PL3039939T3 (pl) | Sposoby i aparatura łącza wstępującego dla wielu użytkowników | |
| IL252087B (en) | Methods of selecting t cell line and donor thereof for adoptive cellular therapy | |
| DK3301447T3 (da) | Anti-tumorrespons til modificerede selvepitoper | |
| DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
| EP2919168A4 (en) | PORTABLE ELECTRONIC DEVICE | |
| EP2964120A4 (en) | ILIAKALVERBINDER | |
| HRP20170840T1 (hr) | Supstituirani ksantini i metode njihove uporabe | |
| DK4032985T3 (da) | Mikropeptider og anvendelse deraf til at modulere genekspressionen | |
| DK3065771T3 (da) | Fremgangsmåder og sammensætninger til vedvarende immunterapi | |
| DK2657517T3 (da) | System og fremgangsmåde til vindmøllestyring | |
| LT3007726T (lt) | Tautopatijos gydymo būdai | |
| DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
| DK3078724T6 (da) | Fremgangsmåde til fremstilling af biodiesel og relaterede produkter |